Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome.
Li–Fraumeni syndrome
TP53
medulloblastoma
survival
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
08 12 2023
08 12 2023
Historique:
pmc-release:
28
06
2024
medline:
17
12
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
ppublish
Résumé
The prognosis for Li-Fraumeni syndrome (LFS) patients with medulloblastoma (MB) is poor. Comprehensive clinical data for this patient group is lacking, challenging the development of novel therapeutic strategies. Here, we present clinical and molecular data on a retrospective cohort of pediatric LFS MB patients. In this multinational, multicenter retrospective cohort study, LFS patients under 21 years with MB and class 5 or class 4 constitutional TP53 variants were included. TP53 mutation status, methylation subgroup, treatment, progression free- (PFS) and overall survival (OS), recurrence patterns, and incidence of subsequent neoplasms were evaluated. The study evaluated 47 LFS individuals diagnosed with MB, mainly classified as DNA methylation subgroup "SHH_3" (86%). The majority (74%) of constitutional TP53 variants represented missense variants. The 2- and 5-year (y-) PFS were 36% and 20%, and 2- and 5y-OS were 53% and 23%, respectively. Patients who received postoperative radiotherapy (RT) (2y-PFS: 44%, 2y-OS: 60%) or chemotherapy before RT (2y-PFS: 32%, 2y-OS: 48%) had significantly better clinical outcome then patients who were not treated with RT (2y-PFS: 0%, 2y-OS: 25%). Patients treated according to protocols including high-intensity chemotherapy and patients who received only maintenance-type chemotherapy showed similar outcomes (2y-PFS: 42% and 35%, 2y-OS: 68% and 53%, respectively). LFS MB patients have a dismal prognosis. In the presented cohort use of RT significantly increased survival rates, whereas chemotherapy intensity did not influence their clinical outcome. Prospective collection of clinical data and development of novel treatments are required to improve the outcome of LFS MB patients.
Sections du résumé
BACKGROUND
The prognosis for Li-Fraumeni syndrome (LFS) patients with medulloblastoma (MB) is poor. Comprehensive clinical data for this patient group is lacking, challenging the development of novel therapeutic strategies. Here, we present clinical and molecular data on a retrospective cohort of pediatric LFS MB patients.
METHODS
In this multinational, multicenter retrospective cohort study, LFS patients under 21 years with MB and class 5 or class 4 constitutional TP53 variants were included. TP53 mutation status, methylation subgroup, treatment, progression free- (PFS) and overall survival (OS), recurrence patterns, and incidence of subsequent neoplasms were evaluated.
RESULTS
The study evaluated 47 LFS individuals diagnosed with MB, mainly classified as DNA methylation subgroup "SHH_3" (86%). The majority (74%) of constitutional TP53 variants represented missense variants. The 2- and 5-year (y-) PFS were 36% and 20%, and 2- and 5y-OS were 53% and 23%, respectively. Patients who received postoperative radiotherapy (RT) (2y-PFS: 44%, 2y-OS: 60%) or chemotherapy before RT (2y-PFS: 32%, 2y-OS: 48%) had significantly better clinical outcome then patients who were not treated with RT (2y-PFS: 0%, 2y-OS: 25%). Patients treated according to protocols including high-intensity chemotherapy and patients who received only maintenance-type chemotherapy showed similar outcomes (2y-PFS: 42% and 35%, 2y-OS: 68% and 53%, respectively).
CONCLUSIONS
LFS MB patients have a dismal prognosis. In the presented cohort use of RT significantly increased survival rates, whereas chemotherapy intensity did not influence their clinical outcome. Prospective collection of clinical data and development of novel treatments are required to improve the outcome of LFS MB patients.
Identifiants
pubmed: 37379234
pii: 7209539
doi: 10.1093/neuonc/noad114
pmc: PMC10708940
doi:
Substances chimiques
Tumor Suppressor Protein p53
0
Types de publication
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2273-2286Subventions
Organisme : Cancer Research UK
ID : DRCRPG-NOV22/100002
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS122987
Pays : United States
Organisme : NINDS NIH HHS
ID : R56 NS122987
Pays : United States
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Cancer Cell. 2017 Jun 12;31(6):737-754.e6
pubmed: 28609654
Trends Genet. 2021 Mar;37(3):235-250
pubmed: 33272592
Genome Biol. 2011;12(4):R41
pubmed: 21527027
Lancet Oncol. 2017 Jul;18(7):958-971
pubmed: 28545823
J Clin Oncol. 2015 Jul 20;33(21):2345-52
pubmed: 26014290
Acta Neuropathol. 2012 Apr;123(4):465-72
pubmed: 22134537
Biostatistics. 2004 Oct;5(4):557-72
pubmed: 15475419
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Lancet Oncol. 2018 Jun;19(6):785-798
pubmed: 29753700
Am J Med Genet A. 2017 Apr;173(4):1017-1037
pubmed: 28168833
J Clin Oncol. 2010 Dec 10;28(35):5188-96
pubmed: 21060032
Neuro Oncol. 2015 Oct;17 Suppl 4:iv1-iv62
pubmed: 26511214
JCO Precis Oncol. 2020 Oct 2;4:
pubmed: 33163847
Nat Med. 2023 Apr;29(4):917-926
pubmed: 36928815
Radiat Oncol. 2010 Nov 08;5:104
pubmed: 21059199
J Natl Cancer Inst. 1998 Apr 15;90(8):606-11
pubmed: 9554443
Acta Neuropathol. 2016 Jun;131(6):821-31
pubmed: 27040285
Neuro Oncol. 2021 Aug 2;23(8):1215-1217
pubmed: 34185090
Eur J Hum Genet. 2020 Oct;28(10):1379-1386
pubmed: 32457520
Fam Cancer. 2021 Oct;20(4):273-277
pubmed: 33634344
Anticancer Res. 2015 May;35(5):3013-7
pubmed: 25964589
Hum Mutat. 2021 Mar;42(3):223-236
pubmed: 33300245
J Clin Oncol. 2010 Mar 10;28(8):1345-50
pubmed: 20142599
J Clin Oncol. 2013 Aug 10;31(23):2927-35
pubmed: 23835706
Acta Neuropathol. 2013 Jun;125(6):913-6
pubmed: 23670100
J Clin Oncol. 2021 Aug 20;39(24):2685-2697
pubmed: 34110925
Curr Opin Oncol. 2015 Jul;27(4):332-7
pubmed: 26049273
Acta Neuropathol. 2022 Dec;144(6):1143-1156
pubmed: 36181537
Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2716-36
pubmed: 25192704
Cancer Cell. 2014 Mar 17;25(3):393-405
pubmed: 24651015
J Med Genet. 2009 Oct;46(10):689-93
pubmed: 19556618
Lancet Child Adolesc Health. 2020 Dec;4(12):865-874
pubmed: 33222802
Eur J Cancer. 2023 Feb;180:71-84
pubmed: 36542877
J Clin Oncol. 2021 Mar 1;39(7):822-835
pubmed: 33405951
J Clin Oncol. 2011 Apr 20;29(12):e344-6; author reply e347-8
pubmed: 21357788
JAMA Oncol. 2021 Sep 01;7(9):1313-1321
pubmed: 34292305
Nature. 2017 Jul 19;547(7663):311-317
pubmed: 28726821
Clin Transl Radiat Oncol. 2017 Nov 02;7:71-78
pubmed: 29594232
Breast Cancer Res Treat. 2020 May;181(1):181-188
pubmed: 32246378
Acta Neuropathol. 2012 Apr;123(4):473-84
pubmed: 22358457
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
Lancet Oncol. 2016 Sep;17(9):1295-305
pubmed: 27501770
Cancer Med. 2020 Nov;9(21):7954-7963
pubmed: 32931654
Hum Mutat. 2020 Jan;41(1):203-211
pubmed: 31490007
Clin Cancer Res. 2017 Jun 1;23(11):e38-e45
pubmed: 28572266
Int J Cancer. 2001 Aug 20;96(4):238-42
pubmed: 11474498
Lancet Oncol. 2021 Dec;22(12):e562-e574
pubmed: 34856153
Neuro Oncol. 2021 Jul 1;23(7):1163-1172
pubmed: 33377141
Cell. 2012 Jan 20;148(1-2):59-71
pubmed: 22265402